Biogen
BIIB
Market cap $20.6B

140.64 USD

+3.56

2.60%

At close Feb 21, 4:00 PM EST

After hours

140.60

-0.04

0.03%

1 day

2.60%

5 days

0.36%

1 month

-0.24%

3 months

-10.99%

6 months

-31.79%

Year to date

-6.24%

1 year

-36.39%

5 years

-58.23%

10 years

-65.58%

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,605

Healthcare Biological Products, Except Diagnostic Substances

Funds holding %

of 7,139 funds

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

7% less repeat investments, than reductions

Existing positions increased: 285 | Existing positions reduced: 305

1.02% less ownership

Funds ownership: 90.84% [Q3] → 89.82% (-1.02%) [Q4]

8% less funds holding

Funds holding: 895 [Q3] → 819 (-76) [Q4]

13% less call options, than puts

Call options by funds: $308M | Put options by funds: $356M

22% less capital invested

Capital invested by funds: $25.5B [Q3] → $20B (-$5.48B) [Q4]

27% less first-time investments, than exits

New positions opened: 112 | Existing positions closed: 153

63% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 3 (-5) [Q4]

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$135

downside

Avg. target

$191

36%

upside

High target

$265

88%

upside

13 analyst ratings

6 positive

46%

7 neutral

54%

0 negative

Piper Sandler Christopher Raymond 25% 1-year accuracy 8 / 32 met price target	4%downside $135	Neutral Reiterated	18 Feb 2025
Scotiabank George Farmer 29% 1-year accuracy 7 / 24 met price target	59%upside $224	Sector Outperform Maintained	13 Feb 2025
BMO Capital Evan Seigerman 67% 1-year accuracy 10 / 15 met price target	1%downside $139	Market Perform Maintained	13 Feb 2025
Morgan Stanley Matthew Harrison 50% 1-year accuracy 10 / 20 met price target	12%upside $157	Equal-Weight Maintained	13 Feb 2025
Goldman Sachs Salveen Richter 27% 1-year accuracy 4 / 15 met price target	74%upside $245	Buy Maintained	13 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 32 articles about BIIB published over the past 30 days

Neutral

MarketBeat

2 days ago

Biogen Stock Is Mutating Into a Value Play

Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52.

Positive

Market Watch

3 days ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.

Neutral

Business Wire

4 days ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying c.

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$